Ingredient or product comparison
GHK-Cu Differs from Minoxidil: Timeline Comparison
Mechanism of Action Copper-peptide complex activates tissue remodeling genes (TGF-β, VEGF, collagen synthesis). Delivers bioavailable Cu²⁺ to lysyl oxidase and SOD enzymes. ATP-sensitive potassium channel opener. Dilates blood vessels, increases follicle perfu
This source-based comparison does not add ratings or recommend a winner.
- Mechanism of Action
- Copper-peptide complex activates tissue remodeling genes (TGF-β, VEGF, collagen synthesis). Delivers bioavailable Cu²⁺ to lysyl oxidase and SOD enzymes.
- ATP-sensitive potassium channel opener. Dilates blood vessels, increases follicle perfusion. Metabolized to minoxidil sulfate (active form).
- GHK-Cu addresses structural degradation; minoxidil treats perfusion insufficiency. Mechanisms don't overlap.
- Time to Initial Response
- 8–12 weeks for increased hair density in early-stage thinning. Requires extracellular matrix remodeling timeline.
- 3–6 months for visible regrowth. Shedding phase (telogen effluvium) occurs weeks 2–8 as miniaturized hairs cycle out.
- Minoxidil shows faster initial response, but early results are often shedding. GHK-Cu avoids pronounced shedding phase.
- Durability After Discontinuation
- Structural improvements (collagen density, basement membrane integrity) may persist 6–9 months post-treatment if matrix remodeling occurred.
- Complete reversal within 3–4 months. Hair count returns to baseline or lower as miniaturization resumes.
- GHK-Cu's durability depends on whether repair outpaced damage during use. Minoxidil's effect is purely transient.
- Side Effect Profile
- Rare irritation or contact dermatitis. No systemic absorption concerns at topical doses. Safe for daily use.
- Scalp irritation (10–15% of users), unwanted facial hair growth in women, rare cardiovascular effects (hypotension, tachycardia) from systemic absorption.
- GHK-Cu has cleaner safety profile. Minoxidil's side effects are well-documented but manageable for most users.
- Evidence Quality
- In vitro gene expression data robust. Human clinical trials limited to small-scale studies (n<100). Mechanism well-understood but clinical efficacy less validated.
- FDA-approved since 1988. Multiple large-scale RCTs (randomized controlled trials) showing 30–40% hair count increase vs placebo at 48 weeks.
- Minoxidil has decades of clinical validation. GHK-Cu is mechanistically sound but lacks Phase 3-level human data.
- Cost (Monthly)
- $40–$80 for research-grade formulations (1–2% concentration in topical serum). Compounding required for higher concentrations.
- $10–$30 for generic 5% solution or foam. Widely available over-the-counter.
- Minoxidil is significantly more accessible and affordable. GHK-Cu requires sourcing from specialized suppliers like Real Peptides.